Dashboard
Manage Tickers

SUPN


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

crowdstrike-to-rally-more-than-15-here-are-10-top-analyst-forecasts-for-thursday
Crowdstrike To Rally More Than 15%? Here A...
10/09/2025 12:20:44

piper-sandler-upgrades-supernus-pharmaceuticals-to-overweight-raises-price-target-to-65
Piper Sandler Upgrades Supernus Pharmaceut...
10/09/2025 11:54:54

Piper Sandler analyst David Amsellem upgrades Supernus Pharmaceuticals (NASDAQ:SUPN) from Neutral to Overweight and raises t...

cantor-fitzgerald-maintains-overweight-on-supernus-pharmaceuticals-raises-price-target-to-63
Cantor Fitzgerald Maintains Overweight on ...
09/30/2025 14:13:28

Cantor Fitzgerald analyst Kristen Kluska maintains Supernus Pharmaceuticals (NASDAQ:SUPN) with a Overweight and raises the p...

piper-sandler-maintains-neutral-on-supernus-pharmaceuticals-raises-price-target-to-40
Piper Sandler Maintains Neutral on Supernu...
08/29/2025 13:18:21

Piper Sandler analyst David Amsellem maintains Supernus Pharmaceuticals (NASDAQ:SUPN) with a Neutral and raises the price ta...

cantor-fitzgerald-maintains-overweight-on-supernus-pharmaceuticals-raises-price-target-to-46
Cantor Fitzgerald Maintains Overweight on ...
08/06/2025 14:14:31

Cantor Fitzgerald analyst Kristen Kluska maintains Supernus Pharmaceuticals (NASDAQ:SUPN) with a Overweight and raises the p...

supernus-pharmaceuticals-raises-fy2025-sales-guidance-from-600000m-630000m-to-670000m-700000m-vs-632103m-est
Supernus Pharmaceuticals Raises FY2025 Sal...
08/05/2025 20:27:04

Supernus Pharmaceuticals (NASDAQ:SUPN) raises FY2025 sales outlook from $600.000 million-$630.000 million to $670.000 million-$...

supernus-pharmaceuticals-q2-eps-040-beats-011-estimate-sales-180916m-beat-154061m-estimate
Supernus Pharmaceuticals Q2 EPS $0.40 Beat...
08/05/2025 20:09:44

Supernus Pharmaceuticals (NASDAQ:SUPN) reported quarterly earnings of $0.40 per share which beat the analyst consensus estimate...

Core News & Articles
Earnings Scheduled For August 5, 2025
08/05/2025 08:32:54

Core News & Articles
Supernus Pharmaceuticals Clears Antitrust ...
07/28/2025 12:27:21

Supernus Pharmaceuticals, Inc., a Delaware corporation (NASDAQ:SUPN) ("Supernus", and the "Company"), today ann...

these-analysts-revise-their-forecasts-on-sage-therapeutics-following-acquisition-news
These Analysts Revise Their Forecasts On S...
06/17/2025 18:22:48

supernus-pharma-acquires-maker-of-postpartum-depression-drug-zurzuvae-in-795-million-deal
Supernus Pharma Acquires Maker Of Postpart...
06/16/2025 13:45:42

Supernus to acquire Sage Therapeutics for $795 million, gaining Zurzuvae and aiming for $200 million in annual cost synergies b...

Core News & Articles
Supernus Pharmaceuticals Agrees To Buy Sag...
06/16/2025 11:02:32

Proposed acquisition expected to accelerate mid- to long-term revenue and cash flow growth and further diversify revenue base.S...

supernus-pharmaceuticals-affirms-fy2025-sales-guidance-of-60000m-63000m-vs-62469m-est
Supernus Pharmaceuticals Affirms FY2025 Sa...
05/06/2025 20:21:37

Supernus Pharmaceuticals (NASDAQ:SUPN) affirms FY2025 sales outlook from $600.00 million-$630.00 million to $600.00 million-$63...

supernus-pharmaceuticals-q1-2025-gaap-eps-021-sales-149824m-beat-146936m-estimate
Supernus Pharmaceuticals Q1 2025 GAAP EPS ...
05/06/2025 20:20:22

Supernus Pharmaceuticals (NASDAQ:SUPN) reported quarterly losses of $(0.21) per share. The company reported quarterly sales of...

Core News & Articles
Earnings Scheduled For May 6, 2025
05/06/2025 08:32:41

uncovering-potential-supernus-pharmaceuticalss-earnings-preview
Uncovering Potential: Supernus Pharmaceuti...
05/05/2025 17:01:50

cantor-fitzgerald-reiterates-neutral-on-supernus-pharmaceuticals-maintains-36-price-target
Cantor Fitzgerald Reiterates Neutral on Su...
02/26/2025 13:51:30

Cantor Fitzgerald analyst Kristen Kluska reiterates Supernus Pharmaceuticals (NASDAQ:SUPN) with a Neutral and maintains $36 ...

supernus-pharmaceuticals-sees-fy2025-sales-600000m-630000m-vs-62218m-est
Supernus Pharmaceuticals Sees FY2025 Sales...
02/25/2025 21:08:53

Supernus Pharmaceuticals (NASDAQ:SUPN) sees FY2025 sales of $600.000 million-$630.000 million vs $622.18 million analyst estimate.

supernus-pharmaceuticals-q4-eps-027-misses-052-estimate-sales-17416m-beat-15525m-estimate
Supernus Pharmaceuticals Q4 EPS $0.27 Miss...
02/25/2025 21:08:13

Supernus Pharmaceuticals (NASDAQ:SUPN) reported quarterly earnings of $0.27 per share which missed the analyst consensus estima...

earnings-scheduled-for-february-25-2025
Earnings Scheduled For February 25, 2025
02/25/2025 08:32:24

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION